Akamai Technologies CEO Tom Leighton discusses the company's forecast miss. He speaks with Bloomberg's Caroline Hyde.

Akamai Technologies CEO Tom Leighton discusses the company's forecast miss. He speaks with Bloomberg's Caroline Hyde.

Bloomberg Talks curates top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics and entertainment. On Bloomberg Talks, we round up interviews with Fortune 500 CEOs, government officials, well-known investors and business leaders. 

Bloomberg Talks curates top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics and entertainment. On Bloomberg Talks, we round up interviews with Fortune 500 CEOs, government officials, well-known investors and business leaders.

Listen to top interviews from Bloomberg News.

Bloomberg Talks

Curating today’s top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics and entertainment. On Bloomberg Talks, we round up interviews with Fortune 500 CEOs, government officials, well-known investors and business leaders.

Curating today’s top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics and entertainment. On Bloomberg Talks, we round up interviews with Fortune 500 CEOs, government officials, well-known investors and business leaders.

Akamai CEO Talks 2024 Forecast

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/f71479d7-cd9b-4122-a5b4-b16c010dc2de/transcript

Marker 05

Marker 03

Marker 04

Orlando Bravo of Thoma Bravo discusses the complexity of getting technology deals past regulators which is discouraging some buyers, but tie-ups are still possible for those willing to do the work. He talks with Bloomberg's Dani Burger.

Orlando Bravo of Thoma Bravo discusses the complexity of getting technology deals past regulators which is discouraging some buyers, but tie-ups are still possible for those willing to do the work. He talks with Bloomberg's Dani Burger.

Thoma Bravo LLC Co-Founder Orlando Bravo Talks Tech Dealmaking

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/789b64f8-ab11-4647-b617-b18700fea335/transcript

Marker 01

Marker 02

Novo Nordisk is Europe’s most valuable company with booming demand for its blockbuster diabetes and obesity drugs, Ozempic and Wegovy. They’re revolutionizing the weight loss drug industry, with some analysts predicting it could be worth up to $150 billion a year. Elon Musk, Sharon Osborne and Chelsea Handler have all publicly talked about taking Ozempic or Wegovy, and they've had further backing from Oprah Winfrey. The success has also propelled the company's philanthropic foundation to become the world's largest, with more than double the assets of the Gates Foundation. But it's not without controversy, including possible side effects and high prices, with US Senator Bernie Sanders pressing the company to lower the cost of Wegovy. On the latest episode of Leaders with Lacqua, Francine Lacqua travels to the firm’s headquarters in Copenhagen, Denmark. She speaks to chief executive, Lars Fruergaard Jørgensen.

Novo Nordisk is Europe’s most valuable company with booming demand for its blockbuster diabetes and obesity drugs, Ozempic and Wegovy. They’re revolutionizing the weight loss drug industry, with some analysts predicting it could be worth up to $150 billion a year. Elon Musk, Sharon Osborne and Chelsea Handler have all publicly talked about taking Ozempic or Wegovy, and they've had further backing from Oprah Winfrey. The success has also propelled the company's philanthropic foundation to become the world's largest, with more than double the assets of the Gates Foundation. But it's not without controversy, including possible side effects and high prices, with US Senator Bernie Sanders pressing the company to lower the cost of Wegovy. On the latest episode of Leaders with Lacqua, Francine Lacqua travels to the firm’s headquarters in Copenhagen, Denmark. She speaks to chief executive, Lars Fruergaard Jørgensen.

Novo Nordisk CEO Talks Obesity Drugs, Philanthropy

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/e41a8c6b-02e7-4a0d-bf32-b18700ccc689/transcript

Company CEO, Antonio Neri discusses HPE shares trading at a record high after better-than-expected revenue was reported due to sales of servers built for artificial intelligence work. He joins Bloomberg's Ed Ludlow and Caroline Hyde.

Company CEO, Antonio Neri discusses HPE shares trading at a record high after better-than-expected revenue was reported due to sales of servers built for artificial intelligence work. He joins Bloomberg's Ed Ludlow and Caroline Hyde.

HPE CEO Antonio Neri Talks HPE Shares Trading

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/eade0fa8-5979-4f3a-9adc-b1860155c93c/transcript

Akamai CEO Talks 2024 Forecast

In 1 playlist(s)

Bloomberg Talks

Social links

Follow podcast

Recent clips